Business
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder.
About this update from Pavmed Inc.
[{"type":"text","content":"NEW YORK, April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder.","length":540,"tagName":"p"},{"type":"image","alt":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","displaySize":"","headline":null,"caption":"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/inYGNWGEQafGrh4vq.I22w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OQ--/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $18 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.","length":279,"tagName":"p"},{"type":"text","content":"Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners for the offering.","length":80,"tagName":"p"},{"type":"text","content":"The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-291981) declared effective by the Securities and Exchange Commission on March 26, 2026. A final prospectus supplement a...